{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:07:14Z","timestamp":1788826034021,"version":"build-2803163510"},"reference-count":199,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Dent Res"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:p>Beh\u00e7et\u2019s disease (BD) is a multi-system inflammatory disorder dominated clinically by recurrent oral and genital ulceration, uveitis, and erythema nodosum. Beh\u00e7et\u2019s disease runs a chronic course, with unpredictable exacerbations and remissions whose frequency and severity may diminish with time. Beh\u00e7et\u2019s disease typically arises in young adults, although childhood-onset BD has also been reported. The disease can affect both genders and has a worldwide distribution, although it is more prevalent in countries of the ancient Silk Route. The cause of BD remains unknown, although an autoimmune reaction triggered by an infectious agent in a genetically predisposed individual has been suggested. The treatment of BD is symptomatic and empirical, but generally specific to the clinical features of each patient. The majority of affected individuals do not have life-threatening disease, although mortality can be associated with vascular-thrombotic and neurological disease.<\/jats:p>","DOI":"10.1177\/154405910508400302","type":"journal-article","created":{"date-parts":[[2009,1,8]],"date-time":"2009-01-08T19:39:42Z","timestamp":1231443582000},"page":"209-222","source":"Crossref","is-referenced-by-count":70,"title":["Beh\u00e7et\u2019s Disease: A Review"],"prefix":"10.1177","volume":"84","author":[{"given":"L.M.","family":"Al-Otaibi","sequence":"first","affiliation":[{"name":"Oral Medicine, Division of Maxillofacial Diagnostic, Medical & Surgical Sciences, Eastman Dental Institute for Oral Health Care Sciences, UCL, University of London, 256 Gray\u2019s Inn Road, London WC1X 8LD, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Porter","sequence":"additional","affiliation":[{"name":"Oral Medicine, Division of Maxillofacial Diagnostic, Medical & Surgical Sciences, Eastman Dental Institute for Oral Health Care Sciences, UCL, University of London, 256 Gray\u2019s Inn Road, London WC1X 8LD, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.W.J.","family":"Poate","sequence":"additional","affiliation":[{"name":"Oral Medicine, Division of Maxillofacial Diagnostic, Medical & Surgical Sciences, Eastman Dental Institute for Oral Health Care Sciences, UCL, University of London, 256 Gray\u2019s Inn Road, London WC1X 8LD, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2005,3,1]]},"reference":[{"key":"AKMAN-DEMIR-ETAL-1996","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1996.00550070133022"},{"key":"AKOGLU-ETAL-1990","unstructured":"Akoglu TF, Direskeneli H, Yazici H, Lawrence R (1990). TNF, soluble IL-2R and soluble CD-8 in Beh\u00e7et\u2019s disease. J Rheumatol 17:1107\u20131108."},{"key":"AKPOLAT-ETAL-2002","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2002.31721"},{"key":"AKSU-ETAL-1999","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.12.1279"},{"key":"AKTULGA-ETAL-1980","unstructured":"Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y,\n                      et al.\n                      (1980). A double blind study of colchicine in Beh\u00e7et\u2019s disease. Haematologica 65:399\u2013402."},{"key":"AKYOL-ETAL-2002","unstructured":"Akyol M, Dogan S, Kaptanoglu E, Ozcelik S (2002). Systemic isotretinoin in the treatment of Beh\u00e7et\u2019s patients with arthritic symptoms and acne lesions. Clin Exp Rheumatol 20(4 Suppl):S-55."},{"key":"AL-ABOOSI-ETAL-1996","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1996.tb03685.x"},{"key":"AL-DALAAN-ETAL-1994","unstructured":"al Dalaan AN, al Balaa SR, el Ramahi K, al Kawi Z, Bohlega S, Bahabri S,\n                      et al.\n                      (1994). Beh\u00e7et\u2019s disease in Saudi Arabia. J Rheumatol 21:658\u2013661."},{"key":"AL-ETAL-1999","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(99)00165-3"},{"key":"AL-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Al Rawi ZS, Neda AH (2003). Prevalence of Beh\u00e7et\u2019s disease among Iraqis. Adv Exp Med Biol 528:37\u201341.","DOI":"10.1007\/0-306-48382-3_6"},{"key":"ALPSOY-ETAL-1998","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1998.00401.x"},{"key":"ALPSOY-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S,\n                      et al.\n                      (2002). Interferon alfa-2a in the treatment of Beh\u00e7et disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 138:467\u2013471.","DOI":"10.1001\/archderm.138.4.467"},{"key":"ARAL-ETAL-1986","unstructured":"Aral O, Dilsen N, Konice M (1986). Positive skin pathergy reactivity as a genetic marker of Beh\u00e7et\u2019s disease. In: Recent advances in Beh\u00e7et\u2019s disease. Lehner T, Barnes CG, editors. London: Royal Society of Medical Services, pp. 173\u2013175."},{"key":"ARIDOGAN-ETAL-2003","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2003.tb00442.x"},{"key":"AYATA-ETAL-2002","unstructured":"Ayata EM, Celik AF, Melikoglu M, Hamuryudan V, Yazici H (2002). The effect of smoking on oral ulcers (OU) of Beh\u00e7et\u2019s syndrome (BS) (abstract). Berlin: 10th International Congress on Beh\u00e7et\u2019s Disease."},{"key":"AYKUTLU-ETAL-2002","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2002.01102.x"},{"key":"BAHRAM-AND-SPIES-1996","doi-asserted-by":"publisher","DOI":"10.1016\/0923-2494(96)89646-5"},{"key":"BAHRAM-ETAL-1994","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.14.6259"},{"key":"BAIXAULI-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Baixauli A, Calvo J, Tamarit JJ, Campos C, Garcia S, Herrera A (2001). Beh\u00e7et\u2019s disease: retrospective study. Ann Med Interna 18:405\u2013410.","DOI":"10.4321\/S0212-71992001000800002"},{"key":"BANG-ETAL-1997A","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.1997.38.6.428"},{"key":"BANG-ETAL-1997B","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.1997.38.6.437"},{"key":"BANG-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2001.16.5.615"},{"key":"BANG-ETAL-2003","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2003.18.2.231"},{"key":"BANK-ETAL-2003","doi-asserted-by":"publisher","DOI":"10.1067\/mlc.2003.1"},{"key":"BARDAK-1999","unstructured":"Bardak Y (1999). Effects of age and sex on Beh\u00e7et\u2019s disease. J Rheumatol 26:1008\u20131009."},{"key":"BAYRAKTAR-ETAL-1997","unstructured":"Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M (1997). Budd-Chiari syndrome: a common complication of Beh\u00e7et\u2019s disease. Am J Gastroenterol 92:858\u2013862."},{"key":"BEHCET-DISEASE-RESEARCH-COMMITTEE-OF-JAPAN-1974","unstructured":"Beh\u00e7et\u2019s Disease Research Committee of Japan (1974). Beh\u00e7et\u2019s disease: guide to diagnosis of Beh\u00e7et\u2019s disease. Jpn J Ophthalmol 18:291\u2013294."},{"key":"BHAKTA-ETAL-1999","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.8.728"},{"key":"BINDER-ETAL-1987","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/26.4.285"},{"key":"BIRD-STEWART-1986","doi-asserted-by":"publisher","DOI":"10.1136\/ard.45.4.265"},{"key":"BLOBNER-1937","doi-asserted-by":"crossref","unstructured":"Blobner F (1937). Zur rezidivierenden Hypopyoniritis. Z Augenheilkunde 91:129\u2013139.","DOI":"10.1159\/000299174"},{"key":"BONASS-ETAL-1986","unstructured":"Bonass W, Bird-Stewart J, Chamberlain MA (1986). Molecular studies in Beh\u00e7et\u2019s syndrome. In: Recent advances in Beh\u00e7et\u2019s disease. Lehner T, Barnes CG, editors. London: Royal Society of Medical Services, pp. 37\u201341."},{"key":"CAKIR-ETAL-1991","doi-asserted-by":"publisher","DOI":"10.1136\/ard.50.9.634"},{"key":"CARLETTO-ETAL-1997","unstructured":"Carletto A, Pacor ML, Biasi D, Caramaschi P, Zeminian S, Bellavite P,\n                      et al.\n                      (1997). Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Beh\u00e7et\u2019s disease. J Rheumatol 24:1332\u20131336."},{"key":"CELENLIGIL-NAZLIEL-ETAL-1999","doi-asserted-by":"publisher","DOI":"10.1902\/jop.1999.70.12.1449"},{"key":"CENGIZ-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.1007\/s100670170036"},{"key":"CETINEL-ETAL-1998","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00341-0"},{"key":"CHEN-AND-CHANG-2001","unstructured":"Chen YC, Chang HW (2001). Clinical characteristics of Beh\u00e7et\u2019s disease in southern Taiwan. J Microbiol Immunol Infect 34:207\u2013210."},{"key":"CHIKAMORI-ETAL-1990","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a059752"},{"key":"CHO-ETAL-2003","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000081957.90395.4c"},{"key":"CHOUKRI-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(00)00249-4"},{"key":"CHUN-ETAL-1989","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.1989.tb00049.x"},{"key":"COHEN-ETAL-2002","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.2.157"},{"key":"DAVATCHI-ETAL-1992","unstructured":"Davatchi F, Shahram F, Akbarian M (1992). Epidemiology of Beh\u00e7et\u2019s disease Iran. In: Rheumatology APPLAR 1992. Nasution AR, Darmawan J, Isbagio H, editors. Tokyo: Churchill Livingstone, pp. 95\u201398."},{"key":"DAVATCHI-ETAL-1997","unstructured":"Davatchi F, Shahram F, Akbarian M (1997). Beh\u00e7et\u2019s disease: analysis of 3443 cases. APLAR J Rheumatol 1:2\u20135."},{"key":"DAVATCHI-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Davatchi F, Shahram F, Nadji A, Jamshidi AR, Chams C, Chams H,\n                      et al.\n                      (2003). Influence of pathergy test on the accuracy of different diagnosis criteria for Beh\u00e7et\u2019s disease. Adv Exp Med Biol 528:109\u2013112.","DOI":"10.1007\/0-306-48382-3_22"},{"key":"DAVIES-ETAL-1984","doi-asserted-by":"publisher","DOI":"10.1136\/ard.43.1.70"},{"key":"DAVIES-ETAL-1988","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/27.4.300"},{"key":"DEMIROGLU-AND-DUNDAR-1997","doi-asserted-by":"crossref","unstructured":"Demiroglu H, Dundar S (1997). Effects of age, sex, and initial presentation on the clinical course of Beh\u00e7et\u2019s syndrome (letter). South Med J 90:567.","DOI":"10.1097\/00007611-199705000-00024"},{"key":"DEMIROGLU-ETAL-2000","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05131-4"},{"key":"DILSEN-ETAL-1986","unstructured":"Dilsen N, Konice M, Aral O (1986). Our diagnostic criteria of Beh\u00e7et\u2019s disease\u2014an overview. In: Recent advances in Beh\u00e7et\u2019s disease. Lehner T, Barnes CG, editors. London: Academic Press, pp. 177\u2013180."},{"key":"DIRESKENELI-AND-SARUHAN-DIRESKENELI-2003","unstructured":"Direskeneli H, Saruhan-Direskeneli G (2003). The role of heat shock proteins in Beh\u00e7et\u2019s disease. Clin Exp Rheumatol 21:S44\u2013S48."},{"key":"DUNLOP-1979","unstructured":"Dunlop E (1979). Genital and other manifestations of Beh\u00e7et\u2019s disease seen in venereological clinical practice. In: Beh\u00e7et\u2019s syndrome: clinical and immunological features. Lehner T, Barnes G, editors. London: Academic Press, pp. 159\u2013175."},{"key":"EGLIN-ETAL-1982","doi-asserted-by":"crossref","unstructured":"Eglin RP, Lehner T, Subak-Sharpe JH (1982). Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Beh\u00e7et\u2019s syndrome and recurrent oral ulcers. Lancet 2:1356\u20131361.","DOI":"10.1016\/S0140-6736(82)91268-5"},{"key":"EKMEKCI-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Ekmekci P, Boyvat A, Ozdemir E, Gurler A, Gurgey E (2003). Is long term observation of patients with recurrent aphthous stomatitis necessary? Clinical follow-up of 1238 cases. Adv Exp Med Biol 528:127\u2013130.","DOI":"10.1007\/0-306-48382-3_25"},{"key":"ELDEM-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Eldem B, Onur C, Ozen S (1998). Clinical features of pediatric Beh\u00e7et\u2019s disease. J Pediatr Ophthalmol Strabismus 35:159\u2013161.","DOI":"10.3928\/0191-3913-19980501-08"},{"key":"ERGUN-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.117728"},{"key":"ESTRACH-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Estrach C, Mpofu S, Moots RJ (2002). Beh\u00e7et\u2019s syndrome: response to infliximab after failure of etanercept. Rheumatology\n                      (Oxford)\n                      41:1213\u20131214.","DOI":"10.1093\/rheumatology\/41.10.1213-c"},{"key":"FAM-ETAL-1981","doi-asserted-by":"publisher","DOI":"10.1136\/ard.40.5.509"},{"key":"FRESKO-ETAL-1993","doi-asserted-by":"publisher","DOI":"10.1136\/ard.52.8.619"},{"key":"FREYSDOTTIR-ETAL-1999","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.01069.x"},{"key":"GHAYAD-AND-TOHME-1995","unstructured":"Ghayad E, Tohme A (1995). Beh\u00e7et\u2019s disease in Lebanon: report of 100 cases. J Med Liban 43:2\u20137."},{"key":"GONZALEZ-GAY-ETAL-2000","unstructured":"Gonzalez-Gay MA, Garcia-Porrua C, Branas F, Lopez-Lazaro L, Olivieri I (2000). Epidemiologic and clinical aspects of Beh\u00e7et\u2019s disease in a defined area of Northwestern Spain, 1988\u20131997. J Rheumatol 27:703\u2013707."},{"key":"GOOSSENS-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.6.637"},{"key":"GROH-ETAL-1996","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.22.12445"},{"key":"GUL-ETAL-1996","doi-asserted-by":"crossref","unstructured":"Gul A, Ozbek U, Ozturk C, Inanc M, Konice M, Ozcelik T (1996). Coagulation factor V gene mutation increases the risk of venous thrombosis in Behcet\u2019s disease. Br J Rheumatol 35:1178\u20131180.","DOI":"10.1093\/rheumatology\/35.11.1178"},{"key":"GUL-ETAL-2000","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.8.622"},{"key":"GURLER-ETAL-1997","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.1997.38.6.423"},{"key":"HAMURYUDAN-ETAL-1994","unstructured":"Hamuryudan V, Moral F, Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y,\n                      et al.\n                      (1994). Systemic interferon alpha 2b treatment in Beh\u00e7et\u2019s syndrome. J Rheumatol 21:1098\u20131100."},{"key":"HAMURYUDAN-ETAL-1995","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199508033330517"},{"key":"HAMURYUDAN-ETAL-1997","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400425"},{"key":"HASAN-ETAL-1995","doi-asserted-by":"crossref","unstructured":"Hasan A, Childerstone A, Pervin K, Shinnick T, Mizushima Y, van der Zee R,\n                      et al.\n                      (1995). Recognition of a unique peptide epitope of the mycobacterial and human heat shock protein 65-60 antigen by T cells of patients with recurrent oral ulcers. Clin Exp Immunol 99:392\u2013397.","DOI":"10.1111\/j.1365-2249.1995.tb05563.x"},{"key":"HASAN-ETAL-1996","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90868-5"},{"key":"HAUGEBERG-ETAL-2004","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.010975"},{"key":"HIROHATA-ETAL-1992","doi-asserted-by":"publisher","DOI":"10.1016\/0008-8749(92)90207-6"},{"key":"HIROHATA-ETAL-1998","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(98)00165-8"},{"key":"HUONG-ETAL-1997","doi-asserted-by":"publisher","DOI":"10.1136\/ard.56.3.205"},{"key":"IMAI-ETAL-1997","doi-asserted-by":"crossref","unstructured":"Imai H, Motegi M, Mizuki N, Ohtani H, Komatsuda A, Hamai K,\n                      et al.\n                      (1997). Mouth and genital ulcers with inflamed cartilage (MAGIC syndrome): a case report and literature review. Am J Med Sci 314:330\u2013332.","DOI":"10.1097\/00000441-199711000-00010"},{"key":"IMAI-1971","unstructured":"Imai Y (1971). Studies on prognosis and symptoms of Beh\u00e7et\u2019s disease in long term observation. Jpn J Clin Ophthalmol 25:661\u2013694."},{"key":"INALOZ-ETAL-2004","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2004.00547.x"},{"key":"INTERNATIONAL-STUDY-GROUP-FOR-BEHCET-DISEASE-1990","doi-asserted-by":"crossref","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease (1990). Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet 335:1078\u20131080.","DOI":"10.1016\/0140-6736(90)92643-V"},{"key":"IOAKIMIDIS-ETAL-1993","unstructured":"Ioakimidis D, Georganas C, Panagoulis C, Gournizakis A, Iliopoulos A, Kremastinos D,\n                      et al.\n                      (1993). A case of Adamantiadis-Beh\u00e7et\u2019s syndrome presenting as myocardial infarction. Clin Exp Rheumatol 11:183\u2013186."},{"key":"ISOGAI-ETAL-1990A","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9969(90)90113-O"},{"key":"ISOGAI-ETAL-1990B","doi-asserted-by":"publisher","DOI":"10.12938\/bifidus1982.9.1_27"},{"key":"JABER-ETAL-2002","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.4.365"},{"key":"JANKOWSKI-ETAL-1992","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.68.801.566"},{"key":"KAKLAMANI-ETAL-2000","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67908-6"},{"key":"KAKLAMANI-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Kaklamani VG, Tzonou A, Markomichelakis N, Papazoglou S, Kaklamanis PG (2003). The effect of smoking on the clinical features of Adamantiades-Beh\u00e7et\u2019s disease. Adv Exp Med Biol 528:323\u2013327.","DOI":"10.1007\/0-306-48382-3_64"},{"key":"KANEKO-ETAL-1997","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.1997.38.6.444"},{"key":"KANEKO-ETAL-1985","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1985.tb02082.x"},{"key":"KANEKO-SUZUKI-YAMASHITA-NAGAFUCHI-NAKAJIMA-WAKISAKA-1997","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1997.3611265.x"},{"key":"KARI-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.8.933"},{"key":"KATZENELLENBOGEN-AND-FEUERMAN-1965","unstructured":"Katzenellenbogen I, Feuerman EJ (1965). Beitrag zum Morbus Beh\u00e7et Die Bedeutung der spezifschen. Hauthyperraktivit\u00e4t und der Beh\u00e7etin Reaktion Hautarzt 16:13\u201318."},{"key":"KAYA-ETAL-2002","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2002.01060.x"},{"key":"KILBOURNE-AND-HORSEFALL-1951","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1951.03810100079007"},{"key":"KILMARTIN-ETAL-1998","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.6.2.101.4051"},{"key":"KIM-ETAL-1994","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.1994.tb00559.x"},{"key":"KOC-ETAL-1992","unstructured":"Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S,\n                      et al.\n                      (1992). Vascular involvement in Beh\u00e7et\u2019s disease. J Rheumatol 19:402\u2013410."},{"key":"KONE-PAUT-ETAL-1998","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(98)70368-3"},{"key":"KONE-PAUT-ETAL-2002","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.7.655"},{"key":"KONTOGIANNIS-AND-POWELL-2000","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.76.900.629"},{"key":"KOTTER-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2001.580304.x"},{"key":"KRAUSE-ETAL-1998","unstructured":"Krause I, Uziel Y, Guedj D, Mukamel M, Molad Y, Amit M,\n                      et al.\n                      (1998). Mode of presentation and multisystem involvement in Beh\u00e7et\u2019s disease: the influence of sex and age of disease onset. J Rheumatol 25:1566\u20131569."},{"key":"KRAUSE-ETAL-1999","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.5.457"},{"key":"KRAUSE-ETAL-2001","unstructured":"Krause I, Mader R, Sulkes J, Paul M, Uziel Y, Adawi M,\n                      et al.\n                      (2001). Beh\u00e7et\u2019s disease in Israel: the influence of ethnic origin on disease expression and severity. J Rheumatol 28:1033\u20131036."},{"key":"KURAL-SEYAHI-ETAL-2003","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200301000-00006"},{"key":"LAKHANPAL-ETAL-1988","unstructured":"Lakhanpal S, O\u2019Duffy JD, Lie J (1988). Pathology. In: Beh\u00e7et\u2019s disease: a contemporary synopsis. Plotkin G, Calabro J, O\u2019Duffy J, editors. New York: Futura Publishing Company, pp. 102\u2013142."},{"key":"LAMB-AND-YOUNG-1990","unstructured":"Lamb JR, Young DB (1990). T cell recognition of stress proteins. A link between infectious and autoimmune disease. Mol Biol Med 7:311\u2013321."},{"key":"LANNUZEL-ETAL-2002","doi-asserted-by":"publisher","DOI":"10.1007\/s004150200031"},{"key":"LARKIN-AND-LIGHTMAN-1999","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90078-7"},{"key":"LEHNER-1997","doi-asserted-by":"publisher","DOI":"10.3109\/08830189709116842"},{"key":"LEHNER-ETAL-1991","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.59.4.1434-1441.1991"},{"key":"LESPRIT-ETAL-1995","doi-asserted-by":"publisher","DOI":"10.1136\/ard.54.10.860"},{"key":"MAIN-AND-CHAMBERLAIN-1992","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/31.11.767"},{"key":"MAMMO-ETAL-1997","unstructured":"Mammo L, Al Dalaan A, Bahabri SS, Saour JN (1997). Association of factor V Leiden with Beh\u00e7et\u2019s disease. J Rheumatol 24:2196\u20132198."},{"key":"MARSAL-ETAL-1997","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.2.234"},{"key":"MARTINI-1995","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199509000-00015"},{"key":"MASON-AND-BARNES-1969","doi-asserted-by":"publisher","DOI":"10.1136\/ard.28.2.95"},{"key":"MASUDA-ETAL-1989","doi-asserted-by":"crossref","unstructured":"Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989). Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et\u2019s disease. Lancet 1:1093\u20131096.","DOI":"10.1016\/S0140-6736(89)92381-7"},{"key":"MEGE-ETAL-1993","unstructured":"Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H,\n                      et al.\n                      (1993). Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Beh\u00e7et\u2019s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20:1544\u20131549."},{"key":"MELIKOGLU-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.2.212"},{"key":"MELIKOGLU-ETAL-2002","unstructured":"Melikoglu M, Fresko I, Mat C (2002). A double blind placebo controlled trial of etanercept on mucocutaneous lesions of Beh\u00e7et\u2019s syndrome (abstract). Berlin: 10th International Congress on Beh\u00e7et\u2019s Disease."},{"key":"MISHIMA-ETAL-1979","unstructured":"Mishima S, Masuda K, Izawa Y (1979). Beh\u00e7et\u2019s disease in Japan (abstract). Trans Am Ophthalmol Soc 77:225."},{"key":"MIZUKI-AND-OHNO-1996","unstructured":"Mizuki N, Ohno S (1996). Immunogenetic studies of Beh\u00e7et\u2019s disease. Rev Rhum Engl Ed 63:520\u2013527."},{"key":"MIZUKI-ETAL-1992","unstructured":"Mizuki N, Inoko H, Sugimura K, Nishimura K, Nakamura S, Tanaka H,\n                      et al.\n                      (1992). RFLP analysis in the TNF-beta gene and the susceptibility to alloreactive NK cells in Beh\u00e7et\u2019s disease. Invest Ophthalmol Vis Sci 33:3084\u20133090."},{"key":"MIZUKI-ETAL-1995","doi-asserted-by":"publisher","DOI":"10.1016\/0198-8859(94)00159-N"},{"key":"MIZUKI-ETAL-1997","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.1997.38.6.333"},{"key":"MIZUKI-ETAL-2000","unstructured":"Mizuki N, Ota M, Yabuki K, Katsuyama Y, Ando H, Palimeris GD,\n                      et al.\n                      (2000). Localization of the pathogenic gene of Beh\u00e7et\u2019s disease by microsatellite analysis of three different populations. Invest Ophthalmol Vis Sci 41:3702\u20133708."},{"key":"MIZUKI-ETAL-2001A","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2001.580306.x"},{"key":"MIZUKI-ETAL-2001B","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(00)00246-9"},{"key":"MIZUKI-ETAL-2002","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2002.590207.x"},{"key":"MIZUSHIMA-1986","unstructured":"Mizushima Y (1986). Chemotaxis and phagocytosis of leukocytes in Beh\u00e7et\u2019s disease. In: Recent advances in Beh\u00e7et\u2019s disease. Lehner T, Barnes CG, editors. London: Royal Society of Medical Services, pp. 85\u201387."},{"key":"MIZUSHIMA-ETAL-1977","doi-asserted-by":"crossref","unstructured":"Mizushima Y, Matsumura N, Mori M, Shimizu T, Fukushima B, Mimura Y,\n                      et al.\n                      (1977). Colchicine in Beh\u00e7et\u2019s disease (letter). Lancet 2:1037.","DOI":"10.1016\/S0140-6736(77)92945-2"},{"key":"MIZUSHIMA-ETAL-1988","unstructured":"Mizushima Y, Matsuda T, Hoshi K, Ohno S (1988). Induction of Beh\u00e7et\u2019s disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 15:1029\u20131030."},{"key":"MOGULKOC-ETAL-2000","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.2.479"},{"key":"MORELLI-ETAL-1997","doi-asserted-by":"publisher","DOI":"10.1159\/000177401"},{"key":"MOUSA-ETAL-1986","doi-asserted-by":"publisher","DOI":"10.3109\/03009748609092599"},{"key":"MUHAYA-ETAL-2000","doi-asserted-by":"publisher","DOI":"10.1076\/0927-3948(200009)831-KFT141"},{"key":"NAMBA-ETAL-1986","unstructured":"Namba K, Ueno T, Okita M (1986). Beh\u00e7et\u2019s disease and streptococcal infection. Jpn J Ophthalmol 30:385\u2013401."},{"key":"NAZZARO-1966","unstructured":"Nazzaro P (1966). Cutaneous manifestations of Beh\u00e7et\u2019s disease. In: International Symposium on Beh\u00e7et\u2019s Disease in Rome. Monacelli M, Nazzaro P, editors. Karger: Basel, pp. 1\u201324."},{"key":"NISHIYAMA-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-5155(01)00321-5"},{"key":"ODUFFY-1974","unstructured":"O\u2019Duffy JD (1974). Suggested criteria for diagnosis of Beh\u00e7et\u2019s disease (abstract). J Rheumatol 1(Suppl 1):18."},{"key":"ODUFFY-1978","unstructured":"O\u2019Duffy JD (1978). Summary of International Symposium on Beh\u00e7et\u2019s Disease. Istanbul, September 29\u201330, 1977. J Rheumatol 5:229\u2013233."},{"key":"ODUFFY-1994","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199401000-00007"},{"key":"ODUFFY-ETAL-1984","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90753-8"},{"key":"OGUZ-ETAL-1995","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199508033330517"},{"key":"ONER-ETAL-1998","unstructured":"Oner AF, Gurgey A, Gurler A, Mesci L (1998). Factor V Leiden mutation in patients with Beh\u00e7et\u2019s disease. J Rheumatol 25:496\u2013498."},{"key":"ORLOFF-AND-ORLOFF-1999","doi-asserted-by":"publisher","DOI":"10.1016\/S1072-7515(99)00012-5"},{"key":"PANDE-ETAL-1995","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.9.825"},{"key":"PAUL-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2001.580307.x"},{"key":"PORTER-AND-SCULLY-2002","unstructured":"Porter S, Scully C (2002). Aphthous ulcers: recurrent. Clin Evid 8:1397\u20131403."},{"key":"PORTER-ETAL-1998","doi-asserted-by":"publisher","DOI":"10.1177\/10454411980090030401"},{"key":"RAZIUDDIN-ETAL-1998","unstructured":"Raziuddin S, Al Dalaan A, Bahabri S, Siraj AK, al Sedairy S (1998). Divergent cytokine production profile in Beh\u00e7et\u2019s disease. Altered Th1\/Th2 cell cytokine pattern. J Rheumatol 25:329\u2013333."},{"key":"ROBERTSON-AND-HICKLING-2001","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.4.473"},{"key":"RUSSELL-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200115010-00003"},{"key":"SAENZ-ETAL-2004","unstructured":"Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P (2004). Pharmacotherapy for Beh\u00e7et\u2019s syndrome (Cochrane Review). The Cochrane Library. Vol. 2. Chichester, UK: John Wiley & Sons, Ltd."},{"key":"SANZ-ETAL-1998","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1998.tb02955.x"},{"key":"SAYLAN-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Saylan T, Mat C, Fresko I, Melikoglu M (1999). Beh\u00e7et\u2019s disease in the Middle East. Clin Dermatol 17:209\u2013223.","DOI":"10.1016\/S0738-081X(99)00013-9"},{"key":"SFIKAKIS-2002","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.suppl_2.ii51"},{"key":"SFIKAKIS-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05497-6"},{"key":"SFIKAKIS-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S,\n                      et al.\n                      (2004). Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et disease. Ann Intern Med 140:404\u2013406.","DOI":"10.7326\/0003-4819-140-5-200403020-00025"},{"key":"SHAH-ETAL-1992","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(92)31790-7"},{"key":"SHARQUIE-ETAL-2002","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2002.tb00263.x"},{"key":"SHEK-AND-LIM-2002","doi-asserted-by":"crossref","unstructured":"Shek LP, Lim DL (2002). Thalidomide in Beh\u00e7et\u2019s disease. Biomed Pharmacother 56:31\u201335.","DOI":"10.1016\/S0753-3322(01)00154-8"},{"key":"SHIMIZU-ETAL-1979","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(79)90004-0"},{"key":"SIEPMANN-AND-KIRCH-1997","doi-asserted-by":"publisher","DOI":"10.1007\/PL00006848"},{"key":"SILVEIRA-AND-MCGRATH-1992","unstructured":"Silveira L, McGrath H (1992). Smoking controls symptomatology of Beh\u00e7et\u2019s disease (abstract). Arthritis Rheum 35:12S."},{"key":"SIMSEK-ETAL-1991","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1991.tb05883.x"},{"key":"SLOPER-ETAL-1999","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90156-2"},{"key":"SOHN-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04498.x"},{"key":"STUDD-ETAL-1991","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-34-1-39"},{"key":"STUEBIGER-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Stuebiger N, Koetter I, Zierhut M (2000). Complete regression of retinal neovascularization after therapy with interferon alfa in Beh\u00e7et\u2019s disease. Br\n                      J Ophthalmol\n                      84:1437\u20131438.","DOI":"10.1136\/bjo.84.12.1432g"},{"key":"TAKENO-ETAL-1995","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380321"},{"key":"TAN-ETAL-1999","unstructured":"Tan E, Chua SH, Lim JT (1999). Retrospective study of Beh\u00e7et\u2019s disease seen at the National Skin Centre, Singapore. Ann Acad Med Singapore 28:440\u2013444."},{"key":"TANAKA-ETAL-1999","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.7.2.69.4018"},{"key":"TESSLER-AND-JENNINGS-1990","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.74.6.353"},{"key":"TREUDLER-ETAL-1999","doi-asserted-by":"publisher","DOI":"10.1159\/000018197"},{"key":"TSUCHIDA-ETAL-1997","doi-asserted-by":"publisher","DOI":"10.1007\/BF02931965"},{"key":"TURAN-ETAL-1997","unstructured":"Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM (1997). Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Beh\u00e7et\u2019s disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 24:128\u2013132."},{"key":"TUZUN-ETAL-1996","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1996.tb03683.x"},{"key":"UZUN-ETAL-2003","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2003.tb00423.x"},{"key":"VERITY-ETAL-1999A","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(99)00184-1"},{"key":"VERITY-ETAL-1999B","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.1999.540307.x"},{"key":"WHALLETT-ETAL-1999","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/92.12.727"},{"key":"YAZICI-2002","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)01081-6"},{"key":"YAZICI-AND-BARNES-1991","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199142050-00006"},{"key":"YAZICI-AND-OZYAZGAN-1999","doi-asserted-by":"publisher","DOI":"10.1159\/000060761"},{"key":"YAZICI-ETAL-1984A","doi-asserted-by":"publisher","DOI":"10.1136\/ard.43.1.74"},{"key":"YAZICI-ETAL-1984B","doi-asserted-by":"publisher","DOI":"10.1136\/ard.43.6.783"},{"key":"YAZICI-ETAL-1985","unstructured":"Yazici H, Tuzun Y, Tanman AB, Yurdakul S, Serdaroglu S, Pazarli H,\n                      et al.\n                      (1985). Male patients with Beh\u00e7et\u2019s syndrome have stronger pathergy reactions. Clin Exp Rheumatol 3:137\u2013141."},{"key":"YAZICI-ETAL-1996","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.2.139"},{"key":"YAZICI-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Yazici H, Yurdakul S, Hamuryudan V (1998). Beh\u00e7et\u2019s syndrome. In: Rheumatology. Klippel JH, Dieppe PA, editors. London: Mosby, pp. 1\u20136.","DOI":"10.1097\/00002281-199901000-00009"},{"key":"YOKOTA-ETAL-1992","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.1992.tb02083.x"},{"key":"YUCEL-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Yucel AE, Kart-Koseoglu H, Akova YA, Demirhan B, Boyacioglu S (2004). Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Beh\u00e7et\u2019s disease. Rheumatology\n                      (Oxford)\n                      43:394\u2013396.","DOI":"10.1093\/rheumatology\/keh056"},{"key":"YURDAKUL-ETAL-1983","doi-asserted-by":"publisher","DOI":"10.1136\/ard.42.5.505"},{"key":"YURDAKUL-ETAL-1988","unstructured":"Yurdakul S, Gunaydin I, Tuzun Y, Tankurt N, Pazarli H, Ozyazgan Y,\n                      et al.\n                      (1988). The prevalence of Beh\u00e7et\u2019s syndrome in a rural area in northern Turkey. J Rheumatol 15:820\u2013822."},{"key":"YURDAKUL-ETAL-2001","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H"},{"key":"ZOUBOULIS-ETAL-1997","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.1997.38.6.411"},{"key":"ZWIRNER-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Zwirner NW, Fernandez-Vina MA, Stastny P (1998). MICA, a new polymorphic HLA-related antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes. Immunogenetics 47:139\u2013148.","DOI":"10.1007\/s002510050339"}],"container-title":["Journal of Dental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/154405910508400302","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/154405910508400302","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/154405910508400302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:01:42Z","timestamp":1777496502000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/154405910508400302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":199,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1177\/154405910508400302"],"URL":"https:\/\/doi.org\/10.1177\/154405910508400302","relation":{},"ISSN":["0022-0345","1544-0591"],"issn-type":[{"value":"0022-0345","type":"print"},{"value":"1544-0591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}